FROM ILLEGAL DRUG TO LEGAL TREATMENT
The U.S. Food and Drug Administration (FDA) has determined that 3,4-methylenedioxymethamphetamine (MDMA), also known as ecstasy, is a “breakthrough therapy” in the treatment of post-traumatic stress disorder (PTSD). Thanks to this designation, the drug could have a faster path to pharmaceutical approval.
The Multidisciplinary Association for Psychedelic Studies (MAPS) announced the FDA’s ruling last week, revealing that they can now move forward on two of their upcoming “Phase 3” trials. The goal of these trials is to determine how effectively the drug can be used to treat those suffering from PTSD. The trials will include 200 to 300 participants, and the first trial will begin to accept subjects in 2018.